Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/107750Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Darbà, Josep | - |
| dc.contributor.author | Ramírez, Gabriela | - |
| dc.contributor.author | García-Rivero, Juan L. | - |
| dc.contributor.author | Mayoralas, Sagrario | - |
| dc.contributor.author | Pascual, José Francisco | - |
| dc.contributor.author | Vargas, Diego | - |
| dc.contributor.author | Bijedic, Adi | - |
| dc.date.accessioned | 2017-03-02T15:15:56Z | - |
| dc.date.available | 2017-03-02T15:15:56Z | - |
| dc.date.issued | 2017-02 | - |
| dc.identifier.issn | 1178-6981 | - |
| dc.identifier.uri | http://hdl.handle.net/2445/107750 | - |
| dc.description.abstract | The objective of this study was to estimate the economic impact of the introduction of DuoResp® Spiromax®, budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ... | - |
| dc.format.extent | 11 p. | - |
| dc.format.mimetype | application/pdf | - |
| dc.language.iso | eng | - |
| dc.publisher | Dove Medical Press | - |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2147/CEOR.S125301 | - |
| dc.relation.ispartof | Clinicoeconomics and Outcomes Research, 2017, vol. 9, num. February, p. 127-137 | - |
| dc.relation.uri | https://doi.org/10.2147/CEOR.S125301 | - |
| dc.rights | cc-by-nc (c) Darbà, Josep et al., 2017 | - |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
| dc.source | Articles publicats en revistes (Economia) | - |
| dc.subject.classification | Administració de medicaments | - |
| dc.subject.classification | Malalties pulmonars obstructives cròniques | - |
| dc.subject.classification | Tractament tèrmic | - |
| dc.subject.classification | Economia de la salut | - |
| dc.subject.other | Administration of drugs | - |
| dc.subject.other | Chronic obstructive pulmonary diseases | - |
| dc.subject.other | Heat treatment | - |
| dc.subject.other | Medical economics | - |
| dc.title | Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/publishedVersion | - |
| dc.identifier.idgrec | 668396 | - |
| dc.date.updated | 2017-03-02T15:15:56Z | - |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
| dc.identifier.pmid | 28228660 | - |
| Appears in Collections: | Articles publicats en revistes (Economia) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 668396.pdf | 204.4 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
